Good morning, hopefully you had a great weekend and perhaps were lucky enough to have an extended weekend. Here is what I am reading as we start the work week:
- Biogen and Eisai released data from their Alzheimer clinical trial last week and the market responded very positively, but are the results really what they seem (Forbes)?
- The week ahead in biotech, a roundup of conferences, PDUFA dates and Clinical Trials (Benzinga).
- Medtech investing advice from the trenches (Medical Design & Outsourcing).
- According to Deloitte’s second annual real-world evidence benchmarking survery, biopharma is embracing real-world evidence (BioPharma Dive).
MattCorc 